Treatment of primary Sjögren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point?

Author： Meiners Petra M Vissink Arjan Kallenberg Cees GM Kroese Frans GM Bootsma Hendrika

Publisher： Informa Healthcare

ISSN： 1471-2598

Source： Expert Opinion on Biological Therapy, Vol.11, Iss.10, 2011-10, pp. : 1381-1394

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ofatumumab, a human anti-CD20 monoclonal antibody

By Österborg Anders

Expert Opinion on Biological Therapy, Vol. 10, Iss. 3, 2010-03 ,pp. : 439-449

Informa Healthcare

Access to resources Recommend Favorite

Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia

By Stasi Roberto

Expert Opinion on Biological Therapy, Vol. 8, Iss. 4, 2008-04 ,pp. : 527-540

Informa Healthcare

Access to resources Recommend Favorite

CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road

By Gill Saar Porter David L

Expert Opinion on Biological Therapy, Vol. 14, Iss. 1, 2014-01 ,pp. : 37-49

Informa Healthcare

Access to resources Recommend Favorite

Anti-CD37 antibodies for chronic lymphocytic leukemia

By Robak Tadeusz Robak Pawel

Expert Opinion on Biological Therapy, Vol. 14, Iss. 5, 2014-05 ,pp. : 651-661

Informa Healthcare

Access to resources Recommend Favorite

Gene therapeutics in Sjögren’s syndrome

By Bolstad Anne Isine Jonsson Roland

Expert Opinion on Biological Therapy, Vol. 5, Iss. 6, 2005-06 ,pp. : 763-772

Informa Healthcare

Access to resources Recommend Favorite